Please note. Investigational: not approved by the FDA. Information is for clinical and research awareness only. Not a recommendation to use.
No perspectives yet — be the first!
Be the first verified clinician to share a view on Alfatide.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
A radiotracer composed of a pegylated, dimeric arginine-glycine-aspartic acid (RGD) peptide (PRGD2), radiolabeled, via the chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), to a fluorine F 18-aluminum complex (AlF), with potential alphaVbeta3 integrin (vitronectin receptor) imaging activity using positron emission topography (PET).
Alfatide
Not approved by the FDA. Being tested in clinical trials (furthest: Phase 3).
Only small or early studies in people so far.
There is no FDA-approved product with this peptide.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
Only small or early studies in people so far.
Not FDA-approved. In clinical trials (highest phase: Phase 3); 4 trial(s) listed on ClinicalTrials.gov, led by Yantai LNC Biotechnology Singapore PTE. LTD..
Last verified: Nov 11, 2026
Share your pre-launch perspective on Alfatide and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers
